Citadel Advisors
BIOC

Citadel Advisors’s Biocept, Inc. BIOC Stock Holding History

Citadel Advisors’s Portfolio BIOC Stock Details BIOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-160
Closed -$1.63K – 15695
2023
Q1 		$1.63K Sell
160
-1,153
-88% -$16.7K ﹤0.01% 14267
2022
Q4 		$20.9K Sell
1,313
-494
-27% -$10.9K ﹤0.01% 13115
2022
Q3 		$50K Sell
1,807
-2,010
-53% -$59.5K ﹤0.01% 11637
2022
Q2 		$108K Buy
3,817
+1,270
+50% +$57.9K ﹤0.01% 11341
2022
Q1 		$177K Sell
2,547
-326
-11% -$25.6K ﹤0.01% 11669
2021
Q4 		$312K Buy
2,873
+1,390
+94% +$160K ﹤0.01% 10843
2021
Q3 		$178K Buy
1,483
+910
+159% +$106K ﹤0.01% 12149
2021
Q2 		$72K Sell
573
-1,504
-72% -$204K ﹤0.01% 13147
2021
Q1 		$317K Buy
2,077
+1,560
+302% +$283K ﹤0.01% 10734
2020
Q4 		$69K Buy
+517
New +$73.7K ﹤0.01% 10433
2015
Q4 		– Hold
0
– -$12K – 9350
2015
Q3 		– Hold
0
– – – 8412

Other funds holding BIOC

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's BIOC Position: Q2 2023 in Review

Citadel Advisors sold out of Biocept, Inc. (BIOC) in Q2 2023, closing a stake of 274 shares — an estimated $2.79K sold.

Citadel Advisors first reported a position in BIOC in Q3 2015 and held it in 14 quarters. The position peaked at $203K in Q4 2021. 11 funds tracked by Wall St. Rank hold BIOC as of Q2 2023.

  • Citadel Advisors reported no remaining Biocept, Inc. position as of Q2 2023 after selling out during the quarter.
  • Citadel Advisors sold 274 Biocept, Inc. shares in Q2 2023, an estimated $2.79K.
  • Citadel Advisors first reported a position in Biocept, Inc. in Q3 2015 and held it in 14 quarters.
  • Citadel Advisors's Biocept, Inc. position peaked at $203K in Q4 2021.
  • 11 funds tracked by Wall St. Rank held Biocept, Inc. as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.